“Recurrent Malignant Glioma Global Clinical
Trials Review, H1, 2018", a clinical trial report by GlobalData
throws light on the global trial scenario of the recurrent malignant glioma. It
contains the trial numbers, trial enrolment, trial status and covers clinical
trials by region, countries (G7 and E7), regions and phase. A trend analysis of
the past years’ trials enrolment as well as analysis of the status of these
trials, listings of on-going drug trials and a subsequent projection can help
players to identify opportunities, markets and investments.
Gliomas are tumours formed from the
glial cells in human brain that are responsible for the support of the nerve
cells. These are rapidly progressive and highly invasive brain tumours, classified
into four grades depending on the severity of the occurrence. While there has been boom of development
and evolution in research for the treatment of cancer; there has been
comparatively little advancement in treating malignant glioma and reducing the
recurrence of the disease. Novel therapeutics are being worked upon and
organizations are participating in the global clinical trials to find effective
treatments that could increase the survival chances as well as survival span of
the patients.
Some of the market players involved
in these global trials of recurrent malignant glioma is known names of the
global pharma industry. These includes F. Hoffmann-La Roche Ltd, Merck & Co
Inc., Insys Therapeutics Inc., Eisai Co Ltd, AstraZeneca Plc, Novartis AG, Eli
Lilly and Co, Takeda Pharmaceutical Co Ltd, Tactical Therapeutics Inc., Pfizer
Inc.
Current treatments for malignant
glioma are multimodal. These are divided into chemotherapy, targeted drug
therapy and radiation therapy, which are further divided into sub-categories.
When it comes to the global market for glioma therapeutics, it has been dominated
by North America and Europe, driven by their advanced technologies. However,
Asia is believed to be the next competitor in near future, with countries like
China, India, Japan and South Korea, already progressing in their research work
and participation. Companies are eyeing these markets for strategic expansions
and investments. The process is further being aided by support from government
agencies in terms of policies and increase in research funding from private
entities.
The global clinical trials market is
on rise and is expected to show significant growth in next decade. The factors
driving this growth are expected to be, increasing globalization of clinical
trials, advancement in technology and demand for more research in the
biotech-medical field. However a couple of challenges that the market face are
high attrition in the clinical trials-specially in case of cancer treatments
and high prices of new- generation drugs. But, with the increase in population,
diversity in the medical cases, as well as overall development of the emerging
economies; the industry has shifted its focus to these markets. Thanks to the
developments in globalization, new services and avenues have surfaced that now
helps the mid-size and small size organizations and research institutes to have
access to data and research platforms that were earlier only available with the
biotech-pharma giants.
To know more, click on the link below:-
Related Reports:-
Contact Us:-
Ken Research
Ankur Gupta, Head Marketing
& Communications
+91-9015378249
